Attachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cells

Article type: Research Article

Authors: Kouchakzadeh, Hasan^a | Shojaosadati, Seyed Abbas^{a; *} | Mohammadnejad, Javad^b | Paknejad, Malihe^c | Rasaee, Mohammad Javad^d

Affiliations: [a] Biotechnology Group, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, Iran | [b] Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran | [c] Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran | [d] Medical Biotechnology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Correspondence: [*] Corresponding author: Seyed Abbas Shojaosadati, Biotechnology Group, Chemical Engineering Department, Faculty of Engineering, Tarbiat Modares University, P.O. Box 14115-143, Tehran, Iran. Tel.: +98 21 82883341; Fax: +98 21 82883381; E-mail: shoja_sa@modares.ac.ir.

Abstract: With PR81 as a murine monoclonal antibody (mAb) that was prepared against the human breast cancer, the MUC1 receptor specific targeting is possible. In this study, PR81-conjugated bovine serum albumin (BSA) nanoparticles loaded with anticancer drug 5-fluorouracil (5-FU) were developed. Enzyme linked immunosorbant assay (ELISA) results showed high immunoreactivity of PR81 mAb conjugated to nanoparticles towards MUC1 related peptide or native cancerous MUC1 and almost no cross-reaction to non-specific proteins. In vitro experiments were performed to determine the ability of this new drug delivery system on overcoming MCF-7 breast cancer cells in comparison with four other systems. The results revealed that these cell-type specific drug loaded nanoparticles could achieve more cell death as compared to when the 5-FU was used with no carriers. Stability studies of produced drug delivery system proved high immunoreactivity of conjugated PR81 even after 11 days of storage in room temperature.

Keywords: BSA nanoparticle, PR81 mAb, MUC1, MCF7 cell lines, 5-Fluorouracil

DOI: 10.3233/HAB-2012-0261

Journal: Human Antibodies, vol. 21, no. 3-4, pp. 49-56, 2012